Dr. Shahrokh F. Shariat, MD
Associate Professor of Urology and Medical Oncology Director, Bladder Cancer Outcomes and Translational Research Director, Urologic Oncology Fellowship Program Member, Prostate Cancer Institute and LeFrak Center for Robotic Surgery Weill Cornell Medical Center and New York-Presbyterian Hospital New York, NY, USA
Dr. Shariat is an Associate Professor in the Departments of Urology and Medical Oncology at Weill Cornell Medical Center, New York, NY, USA. He has published more than 500 peer-reviewed research papers and a dozen book chapters, is the holder of five patents stemming from his research into prostate and bladder cancer, and is the recipient of various national and international rewards. He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma Collaboration) and prospective clinical trials. He is a member of various academic societies and a journal, meeting abstract, and grant reviewer for numerous national and international organizations. He is an editorial board member of various journals including European Urology, BJU International, World Journal of Urology, Immunotherapy, and Journal of Men’s Health among others. His research focuses on urologic oncology – molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research. Specially, Dr. Shariat’s has been working on the discovery, testing, and validation of molecular markers associated with the biological and clinical behavior of prostate and urothelial cancers. His laboratory research focuses on integrative epigenomics of urothelial carcinoma testing the hypothesis that integrative analysis of epigenetic and genetic settings in urothelial carcinomas can provide a rational basis for more accurately modeling the critical biological pathways involved in mediating the malignant phenotype of these diseases Using epigenomic integrative analyses to determine the identity of transcription factors that contribute mechanistically to aberrant transcriptional programming, his team is designing personalized therapeutic strategies that are being tested in preclinical and clinical models. His research relies on close collaboration with scientists and physician scientists in urology, medical oncology, and molecular biology.